Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells: Research paper

British Journal of Pharmacology

Volumn 159, Issue 7, 2010, Pages 1497-1510

  Tan, Y ^a   Chiow, Kh ^a   Huang, D ^a   Wong, Sh ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Andrographolide; Epidermal growth factor receptor; Transferrin receptor

Indexed keywords

ANDROGRAPHOLIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; TRANSFERRIN RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOSOME; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DITERPENES; DOWN-REGULATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TRANSFERRIN;

EID: 77949863046     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00627.x     Document Type: Article

References (57)

1. Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R et al. (2008). (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 29: 1986 1993.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Antonin W, Holroyd C, Tikkanen R, Honing S, Jahn R (2000). The R-SNARE endobrevin/VAMP-8 mediates homotypic fusion of early endosomes and late endosomes. Mol Biol Cell 11: 3289 3298.
4. Bao Z, Guan S, Cheng C, Wu S, Wong SH, Kemeny DM et al. (2009). A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. Am J Respir Crit Care Med 179: 657 665.
5. Baud V, Karin M (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33 40.
6. Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M et al. (2000). A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 14: 333 338.
7. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J (2009). Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 35: 354 363.
8. Chen JX, Xue HJ, Ye WC, Fang BH, Liu YH, Yuan SH et al. (2009). Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. Biol Pharm Bull 32: 1385 1391.
9. Cheung HY, Cheung SH, Li J, Cheung CS, Lai WP, Fong WF et al. (2005). Andrographolide isolated from Andrographis paniculata induces cell cycle arrest and mitochondrial-mediated apoptosis in human leukemic HL-60 cells. Planta Med 71: 1106 1111.
10. Chinchore Y, Mitra A, Dolph PJ (2009). Accumulation of rhodopsin in late endosomes triggers photoreceptor cell degeneration. Plos Genet 5: e1000377.
11. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006). The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144 158.
12. Dy GK, Adjei AA (2009). Emerging therapeutic targets in non-small cell lung cancer. Proc Am Thorac Soc 6: 218 223.
13. Eskelinen EL, Tanaka Y, Saftig P (2003). At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 13: 137 145.
14. Goding JW, Burns GF (1981). Monoclonal antibody OKT-9 recognizes the receptor for transferrin on human acute lymphocytic leukemia cells. J Immunol 127: 1256 1258.
15. Gold KA, Lee HY, Kim ES (2009). Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115: 922 935.
16. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR et al. (2010). Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 119: 283 293.
17. Hidalgo MA, Romero A, Figueroa J, Cortes P, Concha II., Hancke, JL, Burgos RA (2005). Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 144: 680 686.
18. Hong W (2005). SNAREs and traffic. Biochim Biophys Acta 1744: 120 144.
19. Hopkins CR, Trowbridge IS (1983). Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol 97 : 508 521.
20. Hyatt DC, Ceresa BP (2008). Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Exp Cell Res 314: 3415 3425.
21. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341 354.
22. Iruretagoyena MI, Tobar JA, Gonzalez PA, Sepulveda SE, Figueroa CA, Burgos RA et al. (2005). Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther 312: 366 372.
23. Kang CS, Pu PY, Li YH, Zhang ZY, Qiu MZ, Huang Q et al. (2005). An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J Neurooncol 74: 267 273.
24. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY (2006). Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 8: 58 70.
25. Kim TG, Hwi KK, Hung CS (2005). Morphological and biochemical changes of andrographolide-induced cell death in human prostatic adenocarcinoma PC-3 cells. In Vivo 19: 551 557.
26. Kirisits A, Pils D, Krainer M (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int J Biochem Cell Biol 39: 2173 2182.
27. Kodama T, Hayasaka S, Setogawa T (1995). Immunohistochemical localization of epidermal growth factor receptor and epithelial antigen in tumors of the human conjunctiva, eyelid, lacrimal gland, and orbit. Graefes Arch Clin Exp Ophthalmol 233: 672 676.
28. Kumar RA, Sridevi K, Kumar NV, Nanduri S, Rajagopal S (2004). Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol 92: 291 295.
29. Lafky JM, Wilken JA, Baron AT, Maihle NJ (2008). Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785: 232 265.
30. Le Roy C, Wrana JL (2005). Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6: 112 126.
31. Lepelletier Y, Camara-Clayette V, Jin H, Hermant A, Coulon S, Dussiot M et al. (2007). Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 67: 1145 1154.
32. Li J, Cheung HY, Zhang Z, Chan GK, Fong WF (2007). Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species. Eur J Pharmacol 568: 31 44.
33. Manikam SD, Stanslas J (2009). Andrographolide inhibits growth of acute promyelocytic leukaemia cells by inducing retinoic acid receptor-independent cell differentiation and apoptosis. J Pharm Pharmacol 61: 69 78.
34. Maxfield FR, McGraw TE (2004). Endocytic recycling. Nat Rev Mol Cell Biol 5: 121 132.
35. Mese H, Sasaki A, Nakayama S, Alcalde RE, Matsumura T (2000). The role of caspase family protease, caspase-3 on cisplatin-induced apoptosis in cisplatin-resistant A431 cell line. Cancer Chemother Pharmacol 46: 241 245.
36. Nixon RA, Yang DS, Lee JH (2008). Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4: 590 599.
37. Pannecouque C, Daelemans D, De Clercq E (2008). Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 3: 427 434.
38. Panossian A, Hovhannisyan A, Mamikonyan G, Abrahamian H, Hambardzumyan E, Gabrielian E et al. (2000). Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine 7: 351 364.
39. Pike LJ (2005). Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 1746: 260 273.
40. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R (2003). Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol 3: 147 158.
41. Saksena S, Emr SD (2009). ESCRTs and human disease. Biochem Soc Trans 37 (Pt 1 167 172.
42. Sheeja K, Kuttan G (2006). Protective effect of Andrographis paniculata and andrographolide on cyclophosphamide-induced urothelial toxicity. Integr Cancer Ther 5: 244 251.
43. Shi MD, Lin HH, Lee YC, Chao JK, Lin RA, Chen JH (2008). Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chem Biol Interact 174: 201 210.
44. Shimizu M, Shirakami Y, Moriwaki H (2008). Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 9: 1034 1049.
45. Singha PK, Roy S, Dey S (2007). Protective activity of andrographolide and arabinogalactan proteins from Andrographis paniculata Nees. against ethanol-induced toxicity in mice. J Ethnopharmacol 111: 13 21.
46. Stanslas J, Liew PS, Lftlkhar N, Lee CP, Saad S, Lajis N et al. (2001). Potential of AG in the treatment of breast cancer. Eur J Cancer 37 (Suppl. 6 169.
47. Wong SH, Xu Y, Zhang T, Griffiths G, Lowe SL, Subramaniam VN et al. (1999). GS32, a novel Golgi SNARE of 32 kDa, interacts preferentially with syntaxin 6. Mol Biol Cell 10: 119 134.
48. Wong SH, Zhang T, Xu Y, Subramaniam VN, Griffiths G, Hong W (1998). Endobrevin, a novel synaptobrevin/VAMP-like protein preferentially associated with the early endosome. Mol Biol Cell 9: 1549 1563.
49. Wrann MM, Fox CF (1979). Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. J Biol Chem 254: 8083 8086.
50. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X et al. (2004). Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 173: 4207 4217.
51. Yang CS, Wang X, Lu G, Picinich SC (2009a). Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9: 429 439.
52. Yang L, Wu D, Luo K, Wu S, Wu P (2009b). Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells. Cancer Lett 276: 180 188.
53. Yap TA, Carden CP, Kaye SB (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9: 167 181.
54. Zahorowska B, Crowe PJ, Yang JL (2009). Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol 135: 1137 1148.
55. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R et al. (2007). ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051 2058.
56. Zhao F, He EQ, Wang L, Liu K (2008). Anti-tumor activities of andrographolide, a diterpene from Andrographis paniculata, by inducing apoptosis and inhibiting VEGF level. J Asian Nat Prod Res 10: 467 473.
57. Zhou J, Zhang S, Ong CN, Shen HM (2006). Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem Pharmacol 72: 132 144.